Blossom Wealth Management Increases Position in Becton, Dickinson and Company $BDX

Blossom Wealth Management increased its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 6.5% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,498 shares of the medical instruments supplier’s stock after acquiring an additional 92 shares during the quarter. Blossom Wealth Management’s holdings in Becton, Dickinson and Company were worth $258,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also made changes to their positions in BDX. Saudi Central Bank purchased a new position in Becton, Dickinson and Company during the first quarter worth about $26,000. Smallwood Wealth Investment Management LLC purchased a new position in shares of Becton, Dickinson and Company during the 1st quarter worth about $27,000. Alpine Bank Wealth Management purchased a new stake in Becton, Dickinson and Company in the first quarter valued at approximately $29,000. Cornerstone Planning Group LLC increased its position in Becton, Dickinson and Company by 341.4% during the first quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock worth $29,000 after purchasing an additional 99 shares during the last quarter. Finally, Kelly Lawrence W & Associates Inc. CA purchased a new position in Becton, Dickinson and Company during the first quarter worth approximately $31,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently issued reports on BDX shares. Morgan Stanley boosted their price objective on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Wells Fargo & Company lifted their target price on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a report on Friday, August 8th. Argus upped their price target on Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Wall Street Zen raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Finally, Piper Sandler reissued a “neutral” rating and set a $200.00 target price (up previously from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Four equities research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $213.09.

Becton, Dickinson and Company Price Performance

BDX stock opened at $184.59 on Friday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10. Becton, Dickinson and Company has a 1 year low of $163.33 and a 1 year high of $251.99. The firm has a market cap of $52.91 billion, a P/E ratio of 33.20, a price-to-earnings-growth ratio of 1.49 and a beta of 0.27. The stock has a 50-day simple moving average of $188.27 and a 200-day simple moving average of $188.72.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, topping the consensus estimate of $3.40 by $0.28. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The firm had revenue of $5.51 billion for the quarter, compared to analyst estimates of $5.50 billion. During the same period in the previous year, the company posted $3.50 EPS. Becton, Dickinson and Company’s revenue for the quarter was up 10.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, equities analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 30th. Investors of record on Monday, September 8th will be issued a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Monday, September 8th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 74.82%.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,185 shares of the business’s stock in a transaction on Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the transaction, the executive vice president owned 4,887 shares in the company, valued at $881,077.23. The trade was a 19.52% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Claire Fraser sold 917 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the sale, the director directly owned 22,226 shares in the company, valued at approximately $4,167,375. The trade was a 3.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 2,965 shares of company stock worth $551,536 in the last quarter. 0.36% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.